Dapagliflozin (Forxiga®). HTA ID: 23065

Assessment Status Rapid Review Complete
HTA ID 23065
Drug Dapagliflozin
Brand Forxiga®
Indication Dapagliflozin (Forxiga®) is indicated in adults for the treatment of symptomatic chronic heart failure with left ventricular ejection fraction >40%.
Assessment Process
Rapid review commissioned 11/10/2023
Rapid review completed 21/11/2023
Rapid review outcome A full HTA is not recommended. The NCPE recommends that dapagliflozin for the treatment of symptomatic chronic heart failure with left ventricular ejection fraction >40% be considered for reimbursement*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.